A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non–Small Cell Lung Cancer

This publication has 28 references indexed in Scilit:

• Evaluation of the Effects of Food on the Single‐Dose Pharmacokinetics of Trametinib, a First‐in‐Class MEK Inhibitor, in Patients with Cancer
  The Journal of Clinical Pharmacology, 2013
• Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
  Journal of Clinical Oncology, 2013
• Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
  The Lancet Oncology, 2013
• A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
  Nature, 2012
• Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
  JNCI: Journal of the National Cancer Institute, 2012
• Inhibition of Ras for Cancer Treatment: The Search Continues
  Future Medicinal Chemistry, 2011
• Compensatory Pathways Induced by MEK Inhibition Are Effective Drug Targets for Combination Therapy against Castration-Resistant Prostate Cancer
  Molecular Cancer Therapeutics, 2011
• Personalized Medicine in Non–Small-Cell Lung Cancer: Is KRAS a Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy?
  Journal of Clinical Oncology, 2010
• New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
  European Journal of Cancer, 2009
• Estimation of parameters in the beta binomial model
  Annals of the Institute of Statistical Mathematics, 1994